loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Poly Medicure Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Poly Medicure Ltd. 25 May 2026 17:33 PM

Q4FY26 & FY26 Result Announced for Poly Medicure Ltd.

Healthcare Supplies company Poly Medicure announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Revenue from Operations: For Q4FY26, Revenue from Operations stood at Rs 53,451.14 lakh, registering a growth of 8.28% QoQ compared to Rs 49,365.55 lakh in Q3FY26, and a strong increase of 21.25% YoY from Rs 44,082.82 lakh in Q4FY25.
  • Annual Revenue from Operations: For the full year FY26, Revenue from Operations amounted to Rs 1,87,525.92 lakh, reflecting a 12.30% YoY growth from Rs 1,66,983.16 lakh in FY25.
  • Total Income: In Q4FY26, Total Income reached Rs 55,226.79 lakh, up by 6.22% QoQ from Rs 51,991.89 lakh in Q3FY26, and higher by 18.73% YoY compared to Rs 46,513.77 lakh in Q4FY25.
  • Annual Total Income: For FY26, Total Income stood at Rs 1,99,534.14 lakh, an increase of 13.44% YoY against Rs 1,75,895.92 lakh in FY25.
  • Net Profit: Net Profit for Q4FY26 was reported at Rs 6,504.10 lakh, reflecting a decline of 8.15% QoQ from Rs 7,080.89 lakh in Q3FY26, and a decrease of 29.18% YoY from Rs 9,183.42 lakh in Q4FY25.
  • Annual Net Profit: For FY26, Net Profit stood at Rs 32,072.99 lakh, a slight drop of 5.27% YoY compared to Rs 33,855.72 lakh in FY25.
  • Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,993.90 lakh, and for the full year FY26, it amounted to Rs 36,721.58 lakh.

Standalone Financial Highlights:

  • Revenue from Operations: Revenue from Operations for Q4FY26 came in at Rs 44,301.49 lakh, up by 5.77% QoQ from Rs 41,886.15 lakh in Q3FY26, and growing by 5.24% YoY from Rs 42,096.94 lakh in Q4FY25.
  • Annual Revenue from Operations: For FY26, Annual Revenue from Operations was Rs 1,66,246.48 lakh, showing an increase of 3.79% YoY against Rs 1,60,179.98 lakh in FY25.
  • Total Income: Total Income for Q4FY26 was Rs 45,813.68 lakh, registering an increase of 2.17% QoQ against Rs 44,841.37 lakh in Q3FY26, and a 2.97% growth YoY from Rs 44,491.80 lakh in Q4FY25.
  • Annual Total Income: For FY26, Annual Total Income stood at Rs 1,78,238.25 lakh, growing 5.37% YoY from Rs 1,69,157.22 lakh in FY25.
  • Net Profit: Net Profit for Q4FY26 was Rs 8,062.17 lakh, increasing by 2.86% QoQ from Rs 7,838.38 lakh in Q3FY26, but declining by 6.97% YoY from Rs 8,666.02 lakh in Q4FY25.
  • Annual Net Profit: For FY26, Net Profit was Rs 33,598.49 lakh, reflecting a marginal growth of 1.40% YoY from Rs 33,133.47 lakh in FY25.
  • Total Comprehensive Income: Total Comprehensive Income for Q4FY26 was Rs 8,125.00 lakh, and for the full year FY26, it stood at Rs 33,621.11 lakh.

Business & Segment Highlights:

  • Dividend: The Board of Directors recommended a dividend of Rs 3.50 (70%) per Equity Share of Rs 5 each for the financial year 2025-26, subject to the approval of shareholders.
  • Segment Performance: The company's operations fall entirely under "Medical Devices", which is considered to be the only reportable segment by the management. Therefore, overall financial results fully reflect the performance of this single segment.
  • Fund Raising (QIP): The company successfully raised Rs 99,999.98 lakh during the previous year by issuing 53,19,148 equity shares of Rs 5 each at a premium of Rs 1,875 each (issue price of Rs 1,880 per share) to Qualified Institutional Investors on a QIP basis.
  • Strategic Acquisitions:
    • The Group acquired 90% economic rights in the Pendracare Group (comprising Pendracare Holdings BV and Welling Medical BV) through RISOR Holding BV.
    • The Group also acquired 100% economic rights in Medistream SA, Switzerland (comprising Citieffe group) through its wholly owned subsidiary company Poly Medicure BV Netherlands.
  • Resolution Plan Approval: The Hon’ble NCLT of Allahabad approved the company's resolution plan for Himalayan Mineral Water Private Limited (Target Company). An amount of Rs 3,316.00 lakh has been deposited to acquire 100% equity shareholding in the target company.
  • Auditor Appointments: The company approved the re-appointment of M/s. PricewaterhouseCoopers Services LLP and M/s Oswal Sunil & Co. (Chartered Accountants) as Internal Auditors for FY27.

Result PDF

Healthcare Supplies company Poly Medicure announced Q3FY26 results

  • Revenue: Rs 493.7 crore against Rs 424.2 crore during Q3FY25, change 16%.
  • EBITDA: Rs 119.4 crore against Rs 116.1 crore during Q3FY25, change 3%.
  • EBITDA Margin: 24.2% for Q3FY26.
  • PBT: Rs 97.6 crore against Rs 113.2 crore during Q3FY25, change -14%.
  • PAT: Rs 70.8 crore against Rs 85.2 crore during Q3FY25, change -17%.
  • PAT Margin: 13.6% for Q3FY26.
  • EPS: Rs 7 for Q3FY26.

Result PDF

Healthcare Supplies company Poly Medicure announced Q1FY26 results

  • Total Income: Rs 444.9 crore compared to Rs 401.7 crore during Q1FY25, change 10.7%.
  • EBITDA: Rs 106.1 crore compared to Rs 103.8 crore during Q1FY25, change 2.1%.
  • EBITDA Margin: 26.3% for Q1FY26.
  • PAT: Rs 93.1 crore compared to Rs 74.0 crore during Q1FY25, change 25.5%.
  • PAT Margin: 20.9% for Q1FY26

Himanshu Baid, Managing Director, Poly Medicure, said: "We are pleased to share that we started the year on a steady note, with our Domestic revenue continuing to demonstrate strong growth momentum. This is supported by a healthy operating margin, enhanced PAT performance and significant product innovations all while continuing to invest in sustainability, scale, and future capacity through R&D and green initiatives.

Our renal division continues to grow at a robust pace, and with the commercialization of our Critical Care and Cardiology division last year, we are further expanding our presence in the larger Medical Devices industry.

While short term challenges persist due to geopolitical tensions and recent tariff changes, we remain confident about the long term opportunity in for the Indian Medical Devices sector and continue to position ourselves strongly to capture that. We remain steadfast to our vision of “Serving people through innovative healthcare solutions”.

Result PDF

Healthcare Supplies company Poly Medicure announced Q4FY25 & FY25 results

Q4FY25 Financial Highlights:

  • Revenue from operations increased by 17% in Q4FY25 to Rs 440.8 crore, compared to Q4FY24 Rs 378.1 crore; FY25 revenue growth stood at 21%.
  • EBITDA grew by 24% in Q4FY25 on a YoY basis, reflecting our strong earnings capability from core operations. The EBITDA margins improved by 160BPS to 27% in Q4FY25.
  • Profit After Tax (PAT) increased by 34% in Q4FY25 to Rs 91.8 crore compared to Q4FY24 Rs 68.4 crore, ; PAT margin expanded by almost 270BPS to 21% in Q4FY25.

FY25 Financial Highlights:

  • Export revenue for FY25 increased by 24% YoY, driven by continued strong performance in key international markets. Geopolitical tensions and tariff war creating short term demand uncertainty in certain export markets.
  • The domestic quarterly and yearly revenue growth was 24% and 19% respectively on a YoY basis, domestic revenue growth has shown strong traction as the year progressed.
  • The balance sheet position remains strong with liquidity position of Rs 1220 crore as at March 25.
  • Adjusted RoCE was 23.4% for FY25 as compared to 23% in the corresponding previous financial year.
  • Incurred a CAPEX of Rs 325 crore in FY25 reflecting our commitment to create adequate infrastructure to capture future growth opportunities in the sector.

Himanshu Baid, Managing Director, Poly Medicure, said: We are extremely pleased with our continued growth in the business in the Q4 and FY25. Our margins continue to expand at higher scale of operations and that gives us immense confidence to keep investing capital to create additional manufacturing capacities.

FY25 has been a transformative year for Polymed as we commercialised two new divisions, Cardiology and Critical Care. Our renal division continues to grow from strength to strength while the core infusion therapy consolidates its leadership position in clinically driven segments.

The current ongoing geopolitical condition as well as uncertainty created due to US imposed tariffs may create short term pressure on demand in certain export markets. We believe that India MedTech sector is well-positioned to benefit from this situation on a longer term basis as global customers look to create alternate supply chains.

Our investment in 3 new plants is going on strongly, which we believe positions us very strongly to achieve the significant growth opportunities that lie in front of us.

Result PDF

Healthcare Supplies company Poly Medicure announced Q3FY25 results

  • Revenue: Rs 424.2 crore compared to Rs 339.6 crore during Q3FY24, change 24.9%.
  • EBITDA: Rs 116.3 crore compared to Rs 90.9 crore during Q3FY24, change 27.9%.
  • EBITDA margin: 27.4% for Q3FY25.
  • PAT: Rs 85.2 crore compared to Rs 65.0 crore during Q3FY24, change 31.1%.
  • Net Cash: Rs 1074.3 for Q3FY25.
  • ROCE: 23.9% for Q3FY25.

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app